United Laboratories International Unit's Antibiotic Passes Quality, Efficacy Consistency Evaluation
MT Newswires Live03-10
United Laboratories International (HKG:3933) said Ceftriaxone Sodium for Injection has received approval from China's National Medical Products Administration as having passed the consistency evaluation of quality and efficacy for generic drugs, a Friday filing with the Hong Kong bourse said.
The drug was submitted by the Zhongshan Branch of Zhuhai United Laboratories, a unit of the intermediate and finished products and bulk medicine company.
The drug is an antibiotic for the treatment of infections caused by sensitive pathogens, including respiratory tract, abdominal, renal and urinary tract, reproductive system, and preoperative infections.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
